# Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant

> **NCT06768697** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Public Health Clinical Center** · enrollment: 60 (estimated)

## Conditions studied

- COVID - 19

## Interventions

- **BIOLOGICAL:** KFD1(0µg )
- **BIOLOGICAL:** KFD1(20µg)
- **BIOLOGICAL:** KFD1(40µg)
- **BIOLOGICAL:** KFD1(80µg)

## Key facts

- **NCT ID:** NCT06768697
- **Lead sponsor:** Shanghai Public Health Clinical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06768697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06768697, "Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06768697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*